TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07415954: Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

Sponsor: Novo Nordisk A/S · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 270 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$5,544,400

Rescue Site Savings

+$3,652,000

Unlock Full NCT07415954 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07415954 Rescue Dossier →